Shandong Sinobioway Biomedicine Co Ltd (002581) — Financial Flexibility Index
Shandong Sinobioway Biomedicine Co Ltd (002581) has a Financial Flexibility Index of -0.12x as of September 2025. Free cash flow of CN¥-26.32 Million (operating CF CN¥-86.58 Million minus capex CN¥60.26 Million) represents 0% of total liabilities (CN¥221.51 Million). Also explore Shandong Sinobioway Biomedicine Co Ltd (002581) net asset momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shandong Sinobioway Biomedicine Co Ltd Financial Flexibility Index (2007–2024)
Historical Financial Flexibility Index trend for Shandong Sinobioway Biomedicine Co Ltd across 18 annual periods. Check strategic asset allocation of Shandong Sinobioway Biomedicine Co Ltd to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
Year-by-year free cash flow to debt coverage for Shandong Sinobioway Biomedicine Co Ltd. For the full company profile including market capitalisation, see how much is Shandong Sinobioway Biomedicine Co Ltd worth.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.01x | CN¥2.47 Million | CN¥-6.55 Million | CN¥173.61 Million | ▲ +107.2% |
| 2023 | -0.20x | CN¥-32.19 Million | CN¥-36.51 Million | CN¥163.41 Million | ▼ -233.2% |
| 2022 | -0.06x | CN¥-23.02 Million | CN¥-54.49 Million | CN¥389.46 Million | ▼ -214.3% |
| 2021 | 0.05x | CN¥14.83 Million | CN¥-46.02 Million | CN¥286.76 Million | ▼ -84.7% |
| 2020 | 0.34x | CN¥86.21 Million | CN¥18.51 Million | CN¥254.33 Million | ▲ +310.3% |
| 2019 | 0.08x | CN¥84.69 Million | CN¥48.41 Million | CN¥1.03 Billion | ▼ -82.2% |
| 2018 | 0.46x | CN¥682.72 Million | CN¥74.46 Million | CN¥1.47 Billion | ▲ +39.2% |
| 2017 | 0.33x | CN¥359.24 Million | CN¥271.11 Million | CN¥1.08 Billion | ▼ -75.1% |
| 2016 | 1.34x | CN¥214.00 Million | CN¥169.32 Million | CN¥160.16 Million | ▲ +98.2% |
| 2015 | 0.67x | CN¥183.34 Million | CN¥137.73 Million | CN¥271.92 Million | ▼ -86.6% |
| 2014 | 5.01x | CN¥100.70 Million | CN¥80.11 Million | CN¥20.08 Million | ▲ +41.8% |
| 2013 | 3.54x | CN¥125.54 Million | CN¥83.13 Million | CN¥35.49 Million | ▼ -30.4% |
| 2012 | 5.08x | CN¥125.15 Million | CN¥63.04 Million | CN¥24.62 Million | ▼ -10.3% |
| 2011 | 5.67x | CN¥101.58 Million | CN¥74.43 Million | CN¥17.91 Million | ▲ +58.9% |
| 2010 | 3.57x | CN¥115.39 Million | CN¥85.71 Million | CN¥32.34 Million | ▲ +80.4% |
| 2009 | 1.98x | CN¥69.69 Million | CN¥54.06 Million | CN¥35.24 Million | ▼ -30.5% |
| 2008 | 2.85x | CN¥78.00 Million | CN¥46.89 Million | CN¥27.41 Million | ▲ +6.6% |
| 2007 | 2.67x | CN¥30.98 Million | CN¥25.07 Million | CN¥11.60 Million | — |